AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11593992
Drug: Press-coated, time-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Press-coated, time-controlled release tablets containing pseudoephedrine hydrochloride
Trial: 9519217
Drug: Hypo-osmolar aerosol
RxNorm normalized name: polyethylene glycols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-osmolar aerosol (ultrasonically nebulized distilled water, output 2 ml/min-1)
Trial: 7863140
Drug: Vaginal application
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal application of Lactobacillus casei v. rhamnosus twice weekly
Trial: 23447696
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) treatment
Trial: 23447696
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) treatment with TMP-SMX prophylaxis
Trial: 18216764
Drug: Remi-1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remi-1 group (1 ng x mL(‐1) remifentanil)
Trial: 18216764
Drug: Remi-2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remi-2 group (2 ng x mL(‐1) remifentanil)
Trial: 18216764
Drug: Remi-3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remi-3 group (3 ng x mL(‐1) remifentanil)
Trial: 18216764
Drug: Remi-4 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remi-4 group (4 ng x mL(‐1) remifentanil)
Trial: 11101061
Drug: rhuIL-10 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuIL-10 1 microg/kg daily
Trial: 11101061
Drug: rhuIL-10 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhuIL-10 4 microg/kg daily
Trial: 8820468
Drug: Oral dolasetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dolasetron mesylate 50, 100, 150, 200, 250, 300, or 400 mg
Trial: 20055898
Drug: Independent research
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Independent research programme on drugs funded by the Italian Medicines Agency (AIFA)
Trial: 18374405
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy with alum-adsorbed grass pollen vaccine (Alutard SQ)
Trial: 12645994
Drug: RWJ-270201 (BCX-1812)
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-270201 (BCX-1812) 100 mg/qd
Trial: 12645994
Drug: RWJ-270201 (BCX-1812)
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-270201 (BCX-1812) 200 mg/qd
Trial: 12645994
Drug: RWJ-270201 (BCX-1812)
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-270201 (BCX-1812) 800 mg on Days 1-5
Trial: 2515342
Drug: Anti‐schistosomal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐schistosomal drugs plus prednisolone (Group II)
Trial: 2515342
Drug: Anti‐schistosomal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐schistosomal drugs plus cyclosporine (Group III)
Trial: 2515342
Drug: Anti‐schistosomal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐schistosomal drugs (Group I)
Trial: 345749
Drug: Gradual reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual reduction of neuroleptic drugs (mean 75 mg equivalent of chlorpromazine)
Trial: 345749
Drug: Maintained on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintained on matched dosages of neuroleptics (mean 150 mg equivalent of chlorpromazine)
Trial: 345749
Drug: Gradual reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual reduction of neuroleptic drugs (mean 8 mg equivalent of chlorpromazine)
Trial: 20177118
Drug: IM IFNbeta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM IFNbeta‐1a 30 microg once weekly plus placebo (n = 12)
Trial: 20177118
Drug: IM IFNbeta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM IFNbeta‐1a 60 microg once weekly plus placebo (n = 11)
Trial: 20177118
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice weekly (n = 22)
Trial: 18950449
Drug: SGB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB with 10 administrations of 10 mg levobupivacaine every other day for 10 treatments, followed by one administration per month for 6 months
Trial: 18950449
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg/day and gabapentin 1800 mg/day orally for 6 months, followed by SGB therapy in the 7th month
Trial: 16669726
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Paroxetine + Psychotherapy)
Trial: 16669726
Drug: Medication +
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication + Psychological therapy
Trial: 12904810
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg tablet
Trial: 9594180
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no THAM treatment)
Trial: 3907641
Drug: 5,6-benzo-alpha-pyrone/troxerutin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,6-benzo-alpha-pyrone/troxerutin combination (Venalot Depot)
Trial: 29735457
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate solution wet compress
Trial: 12095495
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral hormonal contraception (Cileste: 250 microg of norgestimat and 35 microg of ethinylestradiol; Marvelon: 150 microg of desogestrel and 30 microg of ethinylestradiol)
Trial: 10068412
Drug: Bedtime insulin
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime insulin plus metformin (2 g)
Trial: 10068412
Drug: Bedtime and
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime and morning insulin
Trial: 24216675
Drug: 5‐aminolevulinic acid‐mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐aminolevulinic acid‐mediated photodynamic therapy (ALA‐PDT) for lesions <0.5 cm
Trial: 24216675
Drug: ALA‐PDT retreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA‐PDT retreatment after cryotherapy or CO2 laser treatment for lesions >2.0‐4.0 cm
Trial: 16120070
Drug: Concomitant users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant users of analgesics
Trial: 12399278
Drug: Phylloquinone supplementation
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone supplementation (500 micro g)
Trial: 12399278
Drug: Phylloquinone supplementation
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone supplementation (1000 micro g)
Trial: 12399278
Drug: Phylloquinone supplementation
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone supplementation (250 micro g)
Trial: 12399278
Drug: Phylloquinone supplementation
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone supplementation (375 micro g)
Trial: 9756471
Drug: Interferon-alpha-2b (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 5 million international units
Trial: 9756471
Drug: Interferon-alpha-2b (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 10 million international units
Trial: 9756471
Drug: Interferon-alpha-2b (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 15 million international units
Trial: 25434316
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (sugarless gum, half an hour three times daily after meals for 3 days)
Trial: 25434316
Drug: High-dose senna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose senna (150 mL senna solution, 300 mg senna the night before colonoscopy and 80 mg sennoside tablet daily for 3 days)
Trial: 20938039
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin daily for 12 weeks
Trial: 20938039
Drug: 162.5 mg
RxNorm normalized name: quinine 162.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 162.5 mg aspirin daily for 12 weeks
Trial: 20938039
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin daily for 12 weeks
Trial: 20938039
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg aspirin daily for 12 weeks
Trial: 20938039
Drug: 1300 mg
RxNorm normalized name: gelatin 1300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1300 mg aspirin daily for 12 weeks
Trial: 7607751
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (ramipril and enalapril)
Trial: 364010
Drug: Fluoride solution
RxNorm normalized name: Apatate with Fluoride Solution
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride solution and/or silver nitrate treatment
Trial: 24906665
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment or placebo
Trial: 19548447
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ganji recipe and FBE
Trial: 1537519
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg chenodeoxycholic acid (CDCA)
Trial: 1537519
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg UDCA
Trial: 1537519
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg UDCA
Trial: 1537519
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg UDCA
Trial: 1537519
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg UDCA
Trial: 1537519
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (no UDCA administration)
Trial: 6375710
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of pindolol 10 mg and clopamide 5 mg
Trial: 6375710
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of pindolol 10 mg and clopamide 5 mg
Trial: 31165854
Drug: Chemotherapy use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy use
Trial: 31165854
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for women aged 50 years and younger with RS 16-25
Trial: 27621440
Drug: Treatment that
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment that framed healthy eating as consistent with adolescent values of autonomy and social justice
Trial: 27621440
Drug: Treatment that
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment that framed healthy eating as consistent with adolescent values
Trial: 22776871
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen twice before cycling
Trial: 22776871
Drug: Cycling without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycling without ibuprofen
Trial: 22776871
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen twice at rest
Trial: 22776871
Drug: Rest without
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest without ibuprofen intake
Trial: 22776871
Drug: Cycling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycling with ibuprofen
Trial: 22776871
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen at rest
Trial: 22776871
Drug: Rest without
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest without ibuprofen
Trial: 9710040
Drug: rhIGF‐I 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I 0.1 mg/kg/day subcutaneously for 9 months
Trial: 2470569
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline infusion for 28 consecutive days)
Trial: 53719
Drug: Intramuscular insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular insulin (small doses)
Trial: 53719
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of insulin (small doses)
Trial: 53719
Drug: Large intravenous
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large intravenous boluses of insulin (control)
Trial: 53719
Drug: Potassium requirements
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium requirements during treatment (both groups)
Trial: 30868497
Drug: Intramuscular parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intramuscular parecoxib (40 mg)
Trial: 30868497
Drug: 1% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% tetracaine gel (control group)
Trial: 22981146
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 to 80 mg for 42 days (dyslipidemic patients)
Trial: 22981146
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg for 21 days (non-patient volunteers)
Trial: 18971794
Drug: Estradiol gel
RxNorm normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol gel 0.1% (1.0 mg/day)
Trial: 18971794
Drug: Estradiol gel
RxNorm normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol gel 0.1% (0.5 mg/day)
Trial: 18971794
Drug: Estradiol gel
RxNorm normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol gel 0.1% (0.25 mg/day)
Trial: 2147834
Drug: Enoximone (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (3.6 mg/kg total dose over 3 hours)
Trial: 28706331
Drug: Branded amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Branded amoxicillin capsule
Trial: 28706331
Drug: Generic amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic amoxicillin capsule
Trial: 23986090
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily (monotherapy)
Trial: 23986090
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg during 15 days intercalated with four 21-day cycles of docetaxel or pemetrexed (combination therapy)
Trial: 15175564
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg daily)
Trial: 30244028
Drug: Conventional multifactorial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional multifactorial treatment
Trial: 27174405
Drug: Nonsplinted implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsplinted implants with ball attachment (BA)
Trial: 27174405
Drug: Splinted implants
RxNorm normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splinted implants with bar attachment (RA)
Trial: 25531996
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri (DSM 17938)
Trial: 17490972
Drug: Inadequate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate protein (IP) group; 0.5 g protein x kg(‐1) x d(‐1)
Trial: 17490972
Drug: Control group;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group; 1.2 g protein x kg(‐1) x d(‐1)
Trial: 16137086
Drug: Oxidized titanium
RxNorm normalized name: cobalt titanium oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidized titanium implants (TiUnite)
Trial: 8901853
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg beta-carotene and 25,000 IU retinyl palmitate (vitamin A) taken daily
Trial: 1906634
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid producing bacteria (Lactobacillus acidophilus and Bifidobacterium bifidum) with 500 mg ampicillin t.i.d. for 7 days
Trial: 1906634
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 500 mg ampicillin t.i.d. for 7 days
Trial: 6319633
Drug: Stress Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress Management Program (SMP) consisting of eight weekly one-hour sessions of relaxation response, imagery, and diaphragmatic breathing; caffeine intake reduction
Trial: 12782826
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding
Trial: 26979433
Drug: Control (sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sucrose 50 g + deionized water 100 g)
Trial: 22741171
Drug: Food-based intervention
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-based intervention to optimize dietary vitamin E intake to 15 mg/day
Trial: 8643968
Drug: Paclitaxel 250
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 250 mg/m2 combined with carboplatin (AUC 6)
Trial: 8643968
Drug: Paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 225 mg/m2 combined with carboplatin (AUC 6)
Trial: 481481
Drug: Melphalan, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan, cyclophosphamide, carmustine, and prednisone in concurrent schedule (Group C)
Trial: 481481
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (A, B, C)
Trial: 31131743
Drug: Long-duration treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-duration treatment (300 hours) with applied technology and motor learning.
Trial: 25809877
Drug: solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 5 mg once daily
Trial: 24010993
Drug: Valganciclovir (VGCV)
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir (VGCV) dosing appropriate for most patients
Trial: 24010993
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance <60 mL/min
Trial: 17826341
Drug: Idebenone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone (5 mg/kg, 15 mg/kg, and 45 mg/kg)
Trial: 17826341
Drug: Idebenone (high-dose)
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Idebenone (high-dose)
Trial: 15036546
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid test
Trial: 11753789
Drug: Oxaliplatin (l-OHP)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (l-OHP) plus 5-fluorouracil and leucovorin (5-FU/LV)
Trial: 11753789
Drug: Oxaliplatin (l-OHP)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (l-OHP) in combination with 5-FU/LV